Loading
QL1706 is an experimental small-molecule drug from Qilu Pharmaceutical in phase 3 trials for non-small-cell lung cancer and colorectal cancer, with its target not yet stated publicly.
QL1706 (PSB205) is a small-molecule drug developed by Qilu Pharmaceutical. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: QL1706(5mg/kg Q3W IV) concomitantly with Platinum-based chemotherapy. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT05487391 (A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection), NCT06686576 (A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer) and NCT05690945 (A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer), in non-small-cell lung cancer and colorectal cancer. The largest, NCT05487391, plans to enrol 632 participants with primary completion expected 2027-08-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.One arm of QL1706 binds its target on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"QL1706" OR ABSTRACT:"QL1706" OR TITLE:"PSB205" OR ABSTRACT:"PSB205" OR TITLE:"Iparomlimab and Tuvonralimab，PSB205" OR ABSTRACT:"Iparomlimab and Tuvonralimab，PSB205") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about QL1706, not a curated reading list.
Shares A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors, Qilu Pharmaceutical, Non-small-cell lung cancer and the tag pipeline.
Shares A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors, Qilu Pharmaceutical, Non-small-cell lung cancer and the tag pipeline.
Shares Qilu Pharmaceutical, Non-small-cell lung cancer and the tag pipeline.
Shares Qilu Pharmaceutical, Non-small-cell lung cancer and the tag pipeline.
Shares Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.